Johnson & Johnson reports TREMFYA fistula remission data
New data show TREMFYA delivered durable fistula remission through 48 weeks in Crohn’s disease patients with perianal fistula; the announcement describes it as the only IL-23 to do so.
New data show TREMFYA delivered durable fistula remission through 48 weeks in Crohn’s disease patients with perianal fistula; the announcement describes it as the only IL-23 to do so.